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INTRODUCTION: 
A number of methods and techniques have been used in the 
manufacturing of oral extended release dosageforms. 
Probably the simplest and least expensive way to control 
the release of an active agent is to disperse it in an inert 
polymeric matrix. In polymeric system, the active agent is 
physically blended with the polymer powder and then fused 
together by compression moulding, which is a common 
process in the pharmaceutical industry. These dosage forms 
are designed to deliver the drug at a controlled and 
predetermined rate, thus maintaining a therapeutically 
effective concentration of the drug in the systemic 
circulation for a long period of time and therefore reducing 
the frequency of dosing and improving patient compliance. 
Hydrophobic materials for an insoluble matrix carrier and 
water-soluble hydrophilic materials have been reported as 
the most commonly used matrix carriers.1Verapamil HCl is 
a water-soluble phenyl-alkyl amine derivative, which has 
been used widely in the treatment of the hypertension, 
angina pectoris and arrhythmias.2,3 Hydrophilic matrix 
tablets offer precise modulation of drug release through 
manipulation of a small number of formulation factors4. 
Hydroxypropylmethylcellullose (HPMC), is a hydrophilic 
polymer which is used to control drug release from several 
pharmaceutical systems because of its non-toxic nature, 
easy compression, swelling properties and accommodation 
for high levels of drug. In HPMC matrix systems, drug 
release profiles are strongly influenced by the kind of 
polymer, its proportion in the formulation and its viscosity 
grade
5
. However, fillers which are used in these systems 
play a significant role on drug release. While the addition of 
a soluble filler (i.e. lactose) to HPMC matrix systems 
increases porosity which leads to rapid diffusion of drug 
and also increases the rate of the polymer erosion which 
results in acceleration of drug release, the addition of an 
insoluble filler (i.e. calcium phosphate dihydrate) can 
inversely effect the release of drug from these systems 
dependent on its level6. HPMC and lactose combinations to 
form an erodible hydrophilic gel matrix system have 
previously been used successfully to produce controlled 
release preparations7. However, swollen hydrophilic matrix 
systems have generally showed a nearly first order drug 
release profile. In hydrophilic matrix systems, the 
dissolution of the drug present at the surface of the matrix 
causes an initially high release rate of drug, followed by a 
rapidly declining drug release rate due to swelling and 
consequent increasing of the dissolution path-length of the 
matrix8-12. To overcome this undesirable behavior, various 
matrix geometries have been recommended to achieve an 
almost constant release rate of drug with time. One of these 
techniques relies on the use of multi-layered matrix tablets 
as a drug delivery device13. Multi-layered matrix tablet is a 
drug delivery device, which comprises a matrix core 
containing the active solute and one, or more barriers 
(modulating layers) incorporated during the tabletting 
process. A three-layered matrix tablet consists of drug core 
layer sandwiched by the external modulating layers. The 
modulating layers which contain a hydrophilic polymer, 
usually HPMC14, delay the interaction of active solute with 
dissolution medium, by limiting the surface available for 
the solute release and at the same time controlling solvent 
penetration rate15-17. Thus burst effect can be smoothened 
and the release can be maintained at a relatively constant 
level during the barrier layers` swelling and erosion 
process. When the swollen barriers are erosion dominated 
the surface available for drug release slowly increases16.By 
this way, combining a time-dependent control of the 
hydration rate of the device with the reduction of tablet 
surface exposed to the dissolution medium, it is feasible to 
achieve a linear drug release profile. Some of the 
advantages of three-layered matrix systems include the 
maximum flexibility in drug release patterns, ease of 
manufacturing, total system solubility and total release of 
drug13,18,19. 
ABSTRACT 
Matrix tablets of Verapamil Hydrochloride were formulated as sustained release tablet employing sodium alginate, hydroxyl 
propyl methyl cellulose polymer, Ethyl cellulose and the sustainedrelease tablets was investigated. Sustained release matrix 
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results of dissolution studies indicated that formulation F8, the most successful of the study. An increase in release kinetics of 
the drug was observed on decreasing polymer concentration.  
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MATERIALS AND METHODS 
Verapamil hydrochloride was obtained from Cadila 
Pharmaceutical Limited, Dholka, HPMC E4M, a grade of 
HPMC, was procured from Dow Chemical Company, 
Microcrystalline cellulose, was procured from FMC 
Biopolymer,Lactose monohydrate was procured from 
DMV-Fonterra, Magnesium stearate was procured from 
Ferro Corporation. Materials and excipients used in 
preparing tablets. All other ingredients used throughout the 
study were of analytical grade and were used as received. 
Preparation of matrix tablets: 
Matrix tablets, each containing 240 mg Verapamil 
Hydrochloride, were prepared by wet granulation 
technique. The drug polymer concentration was developed 
to adjust drug release and to keep total weight of tablet 
constant for all the fabricated batches under experimental 
conditions of preparations. The total weight of the matrix 
tablets was 430 mg with different drug polymer (HPMC, 
Sodium Alginate, EthylCelluose) concentration. A batch of 
500 tablets was prepared in each formula. The composition 
of tablets is shown in Table 1. Lactose monohydrate and 
Microcrystallinecellulose was incorporated as diluent 
excipient to maintain tablet weight constant. The 
ingredients Verapamil Hydrochloride, HPMC, Lactose 
monohydrate and Microcrystalline cellulosewere passed 
through sieve no. 20 and mixed in a polybag for 10 
minutes. The powder blend was granulated using 
granulating fluid HPMC 5cps dissolved in Purified water 
with constant stirring using glass rod till clear solution. Mill 
the wet granules through multimill by using 5.0 mm screen 
at medium speed and knives forward direction. Dry the wet 
mass in fluid bed drier at ambient temperature initially for 
5-10 minutes and then at inlet temperature of 50ºC-60ºC. 
The dried blend was sifted through sieve no. 16 and retain 
on sieve no. 16, pass the granules through co-mill by using 
2.0 mm screen at 500 – 800 RPM. The granules was then 
lubricated with magnesium stearatepass through sieve no. 
40 and compressed into tablets on a 18-station single rotary 
machine using 14.50×6.50 mm, capsule shaped punches 
with bisecting line on upper punch and pain surface on 
lower punch. 
Evaluation of tablets:  
The prepared matrix tablets were evaluated for hardness, 
weight variation, thickness, friability and drug content. 
Hardness of the tablets was tested using a Portable 
Digital Hardness Tester(Inwek, Ukraine). Friability of the 
tablets was determined in a Roche friabilator (Electro Lab). 
The thickness of the tablets was measured by 
verniercallipers. Weight variation test wasperformed 
according to official method. Drug content for Verapamil 
Hydrochloride was carried out by measuring the absorbance 
of samples at 278 nm using Shimadzu 1201 UV/Vis 
spectrophotometer and comparing the drug content from a 
calibrated curve prepared with standard Verapamil 
Hydrochloride in the same medium. 
In vitro drug release studies: 
Drug release studies were carried out according to USP 
XXVII. pH 1.2 0.1N HCl was used for the first two hours 
and pH 6.8 phosphate buffer was used for the following 22 
hours as dissolution media. USP XXVII-Apparatus II was 
used at 50 rpm. Withdraw a specimen of 10 ml of solution 
from a zone midway between the surface of medium and 
top of the paddle, not less than 1 cm from the vessel wall 
and add 10 ml of fresh medium in vessel of the apparatus at 
predetermined time interval. The amount of Verapamil 
Hydrochloride was determined spectrophotometrically 
(UV) at 278 nm.The actual content in samples was read 
from a calibration curve prepared with standard Verapamil 
hydrochloride. 
Stability studies:  
In the present work stability study was carried out for the 
optimized formulation. Optimized batch was strip packaged 
and kept at 40°C with 75% RH for 3 months. Evaluation of 
appearance, drug content and in vitro drug release.20 
 
Table 1: Formula of Verapamil Hydrochloride Tablet 
Ingredients 
(mg/ml) 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Verapamil 
Hydrochloride 
240 240 240 240 240 240 240 240 240 240 
Lactose 
Monohydrate 
19 19 8.5 8.5 8.5 8.5 8.5 8.5 8.5 8.5 
Avicel PH 101 28.5 28.5 13 13 13 13 13 13 13 13 
HPMC E4M 32 - 77.5 77.5 - - - 39 116 51.5 
Sodium Alginate 97 97 77.5 - 77.5 39 116 116 39 51.5 
Ethyl Cellulose - 32 - 77.5 77.5 116 39 - - 51.5 
HPMC 5cps 9 9 9 9 9 9 9 9 9 9 
Purified Water q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Magnesium 
Stearate 
4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 4.5 
 
RESULT AND DISCUSSION: 
The result of hardness and friability of the prepared matrix 
tablets ranged from 10 kp to 15 kp and 0.10 to 0.21 
respectively. The tablet formulations in all the prepared 
batches contained Verapamil hydrochloride within 240 ± 
5% of labeled content. As such, all the batches of the 
fabricated tablets were of good quality with regard to 
hardness, friability and drug content. All tablets complied 
with pharmacopoeial specifications for weight variation and 
friability. Verapamil hydrochloride release from tablets was 
slow and extended over longer periods of time. The results 
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of dissolution studies of formulations F1 to F10 are shown 
in fig. 1. Drug release from the matrix tablets was found to 
increase with decrease in drug polymer concentration.The 
release of drug depends not only on the nature of matrix but 
also the drug polymer concentration. As the percentage of 
polymer increased, the kinetics of release decreased. This 
may be due to structural reorganization of hydrophilic 
HPMC and Sodium Alginate polymer. Increase in 
concentration of HPMC may result in increase in the 
tortuosity or gel strength of the polymer. When HPMC 
polymer is exposed to aqueous medium, it undergoes rapid 
hydration and chain relaxation to form viscous gelatinous 
layer (gel layer). Failure to generate a uniform and coherent 
gel may cause slow drug release12,13. In vitro release studies 
demonstrated that the release of Verapamil Hydrochloride 
from all these formulated matrix tablets can generally be 
modified (fig. 1). According to commercial tablet, modified 
release profile of oral controlled release formulation of 
Verapamil hydrochloride should provide a release of NMT 
30% in 1 hr, 35-60% in 4hrs, 55-80% in 8hrs, 70-95% in 14 
hrs and 81-105% in 24 hrs. Formulation F8 tablet gave 
release profile close to the commercial modified release 
tablet needed for Verapamil Hydrochloride (fig. 1). The 
data for stability studies carried out for F8 batch at 40°C 
with 75% RH for 3 months revealed that no considerable 
differences in drug content and dissolution rate were 
observed (Table 4). It may be concluded from the present 
study that slow, controlled and complete release of 
Verapamil Hydrochloride over a period of 24hrs was 
obtained from matrix tablets (F8). It is also evident from the 
results that formulation F8 is better system for once daily 
SR of Verapamil Hydrochloride. 
 
Table 2: Percentage of drug release 
Formulation 
Percentage of Drug Release (hrs) 
1 hr 2 hrs 4 hrs 8 hrs 12 hrs 16 hrs 20 hrs 22 hrs 24 hrs 
F1 22.1 36.2 56.2 71.5 86.3 93.6 99.3 - - 
F2 26.3 41.2 61.3 82.1 95.1 99.5 - - - 
F3 19.2 26.1 42.6 69.5 82.6 93.7 98.9 - - 
F4 19.3 25.2 38.5 55.1 79.3 91.6 99.8 - - 
F5 21.3 38.6 57.8 72.5 85.1 96.2 99.9 - - 
F6 19.1 35.8 51.9 67.2 81.2 91.5 97.8 99.2 - 
F7 20.0 38.3 55.1 71.2 85.4 95.8 - - - 
F8 19.5 31.2 46.5 64.1 77.5 87.3 94.4 97.1 99.3 
F9 16.1 26.1 41.5 57.3 72.3 80.6 87.6 90.2 93.4 
F10 16.2 25.1 38.1 51.4 63.4 73.2 81.3 85.1 89.9 
 
Table 3: Properties of Compressed Verapamil Hydrochloride Matrix Tablet 
Formulation Weight (mg) Hardness (kp) Thickness (mm) Friability (%) Drug content (%) 
F1 428.9 10.2 5.80 0.13 98.5 
F2 434.6 12.3 5.89 0.16 100.2 
F3 433.1 12.1 5.85 0.13 98.3 
F4 429.3 11.2 5.60 0.19 99.5 
F5 431.6 10.5 5.99 0.14 99.0 
F6 431.9 11.1 5.91 0.20 98.9 
F7 430.9 13.1 5.98 0.13 98.5 
F8 431.5 11.9 5.91 0.16 100.1 
F9 430.5 12.6 5.88 0.12 98.6 
F10 431.1 13.1 5.85 0.15 99.6 
 
Table 4: Stability studies of Formulated F Batch Tablet 
Parameter Initial Tablet Strip pack at 40ºC/75%RH 
Drug Content 100.1 % 
1 Month 2 Month 3 Month 
99.8 % 99.64 % 99.25 % 
 
 
 
 
 
 
 
 
Brijesh et al                                Journal of Drug Delivery & Therapeutics; 2013, 3(1), 55-58   58 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
 
 
Figure 1: Percentage of drug release 
 
CONCLUSION  
In the above view of findings it can be concluded that the 
combination of different hydrophilic polymer are better 
suited for site specific drug delivery system than 
hydrophobic polymer alone. A matrix design of this kind 
can serve as an alternative strategy to enteric film coating 
techniques commonly employed for the design of delayed 
release systems. 
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